ticker nerd logo
Beam Therapeutics Inc

Beam Therapeutics Inc Stock Forecast & Price Prediction

Live Beam Therapeutics Inc Stock (BEAM) Price
$27.52

18

Ratings

  • Buy 10
  • Hold 8
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$27.52

P/E Ratio

-16.00

Volume Traded Today

$1.4M

Dividend

Dividends not available for BEAM

52 Week High/low

49.50/20.84

Beam Therapeutics Inc Market Cap

$2.28B

🛑 Alert: These ten stocks could have higher potential than $BEAM 🛑

Before you buy BEAM you'll want to see this list of ten stocks that have huge potential. Want to see if BEAM made the cut? Enter your email below

BEAM Summary

From what 18 stock analysts predict, the share price for Beam Therapeutics Inc (BEAM) might increase by 78.78% in the next year. This is based on a 12-month average estimation for BEAM. Price targets go from $23 to $80. The majority of stock analysts believe BEAM is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

BEAM Analyst Ratings

About 18 Wall Street analysts have assigned BEAM 10 buy ratings, 8 hold ratings, and 0 sell ratings. This means that analysts expect Beam Therapeutics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on BEAM. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

BEAM stock forecast by analyst

These are the latest 20 analyst ratings of BEAM.

Analyst/Firm

Rating

Price Target

Change

Date

Patrick Trucchio
HC Wainwright & Co.

Buy

$80

Reiterates

Dec 9, 2024
Patrick Trucchio
HC Wainwright & Co.

Buy

$80

Reiterates

Nov 7, 2024
Rick Bienkowski
Leerink Partners

Outperform

$39

Upgrade

Nov 6, 2024
Luca Issi
RBC Capital

Sector Perform

$24

Maintains

Nov 6, 2024
Greg Harrison
Scotiabank

Sector Perform

$24

Initiates

Oct 16, 2024
Luca Issi
RBC Capital

Sector Perform

$27

Reiterates

Sep 19, 2024
Soumit Roy
Jones Trading

Hold


Initiates

Sep 17, 2024
Benjamin Burnett
Stifel

Buy

$69

Maintains

Sep 11, 2024
Patrick Trucchio
HC Wainwright & Co.

Buy

$80

Reiterates

Aug 22, 2024
Luca Issi
RBC Capital

Sector Perform

$27

Reiterates

Aug 7, 2024
Eric Joseph
JP Morgan

Overweight

$48

Maintains

Aug 7, 2024
Gena Wang
Barclays

Equal-Weight

$31

Maintains

Aug 7, 2024
Patrick Trucchio
HC Wainwright & Co.

Buy

$80

Initiates

Jul 23, 2024
Gena Wang
Barclays

Equal-Weight

$33

Maintains

May 8, 2024
David Nierengarten
Wedbush

Outperform

$57

Reiterates

Apr 23, 2024
Kostas Biliouris
BMO Capital

Outperform

$57

Maintains

Mar 27, 2024
Luca Issi
RBC Capital

Sector Perform

$35

Maintains

Feb 28, 2024
Gena Wang
Barclays

Equal-Weight

$42

Maintains

Feb 28, 2024
Eric Joseph
JP Morgan

Overweight

$40

Upgrade

Jan 29, 2024
Greg Harrison
B of A Securities

Neutral

$35

Downgrade

Dec 15, 2023

BEAM Company Information

What They Do: Develops precision genetic medicines for serious diseases.

Business Model: Beam Therapeutics operates as a biotechnology company focused on creating targeted genetic therapies. It generates revenue through the development of specific product candidates in clinical trials, alongside strategic research collaborations with established pharmaceutical companies like Pfizer and Apellis Pharmaceuticals.

Other Information: Founded in 2017 and headquartered in Cambridge, Massachusetts, the company is actively working on several promising therapies including BEAM-101 for sickle cell disease and BEAM-201 for leukemia. Its collaborations with major partners enhance its research capabilities and broaden its therapeutic reach.
BEAM
Beam Therapeutics Inc (BEAM)

When did it IPO

2020

Staff Count

472

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. John M. Evans M.B.A.

Market Cap

$2.28B

Beam Therapeutics Inc (BEAM) Financial Data

In 2023, BEAM generated $377.7M in revenue, which was a increase of 520.01% from the previous year. This can be seen as a signal that BEAM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$24,000

Revenue From 2021

$51.8M

215,916.67 %
From Previous Year

Revenue From 2022

$60.9M

17.51 %
From Previous Year

Revenue From 2023

$377.7M

520.01 %
From Previous Year
  • Revenue TTM $349.6M
  • Operating Margin TTM -746.4%
  • Gross profit TTM $0
  • Return on assets TTM -9.3%
  • Return on equity TTM -18.3%
  • Profit Margin -41.1%
  • Book Value Per Share 9.97%
  • Market capitalisation $2.28B
  • Revenue for 2021 $51.8M
  • Revenue for 2022 $60.9M
  • Revenue for 2023 $377.7M
  • EPS this year (TTM) $-1.58

Beam Therapeutics Inc (BEAM) Latest News

News Image

Mon, 09 Dec 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - BEAM has appointed Sravan K. Emany as its new chief financial officer, effective December 19.

Why It Matters - Leadership changes can impact company strategy and performance. A new CFO may signal shifts in financial management, affecting investor confidence and stock valuation.

News Image

Sun, 08 Dec 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - NHP data indicate that CD117 monoclonal antibody conditioning effectively enabled long-term engraftment of base-edited hematopoietic stem cells and increased Hemoglobin F levels.

Why It Matters - Successful long-term engraftment of base-edited hematopoietic stem cells suggests advancements in gene therapies, potentially boosting biotech stock valuations and attracting investment in innovative treatments.

News Image

Sat, 07 Dec 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - All seven patients treated with BEAM-101 demonstrated over 60% induction of Hemoglobin F (HbF) and a reduction in Hemoglobin S (HbS), indicating positive treatment outcomes.

Why It Matters - Successful HbF induction and HbS reduction in all patients treated with BEAM-101 indicate strong potential for the therapy, likely boosting company stock and attracting investor interest in biotech.

News Image

Fri, 06 Dec 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Beam Therapeutics Inc. has appointed Sravan K. Emany as CFO, effective December 19, 2024. Emany has extensive experience in global operations and finance, previously serving at Ironwood Pharmaceuticals.

Why It Matters - The appointment of a new CFO with extensive experience may signal strategic shifts at Beam Therapeutics, potentially impacting financial stability and growth prospects, influencing investor sentiment.

News Image

Thu, 05 Dec 2024

Sentiment - NEGATIVE

Source - Zacks Investment Research

Summary - Beam Therapeutics (BEAM) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for potential stock movements.

Why It Matters - Earnings reports can signal company performance trends, impacting stock price. Investors will watch for guidance on future growth and potential market reactions.

News Image

Wed, 04 Dec 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Beam Therapeutics Inc. appointed Chirfi Guindo, Merck's chief marketing officer, to its board of directors. Guindo has over 25 years of experience in the pharmaceutical industry.

Why It Matters - Chirfi Guindo's appointment enhances Beam Therapeutics' leadership with extensive pharmaceutical experience, potentially boosting strategic direction and investor confidence in its growth prospects.

...

BEAM Frequently asked questions

The highest forecasted price for BEAM is $80 from Patrick Trucchio at HC Wainwright & Co..

The lowest forecasted price for BEAM is $23 from from

The BEAM analyst ratings consensus are 10 buy ratings, 8 hold ratings, and 0 sell ratings.